Literature DB >> 6661356

Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria.

O Walker, A H Dawodu, A A Adeyokunnu, L A Salako, G Alvan.   

Abstract

Twelve children with acute falciparum malaria were treated with 25 mg/kg chloroquine orally in three divided doses at 24 h intervals. Concentrations of chloroquine and its metabolite, desethylchloroquine, were measured in plasma from the beginning of treatment for up to 7 days using a high pressure liquid chromatography (h.p.l.c.) technique. Chloroquine was detectable in plasma within 30 min of giving the drug. Peak level was reached in 1-8 h after the first dose of 10 mg/kg and the peak concentrations ranged between 65 and 263 ng/ml. Chloroquine concentration declined slowly in plasma after stopping drug administration so that the concentration at the seventh day was 37.5% of the concentration on the third day. The apparent half-life was 3-4 days. Desethylchloroquine was detectable in plasma within 30 min of giving chloroquine and peak levels were reached in 2-12 h. Peak concentration after the first dose of chloroquine ranged between 9 and 62 ng/ml. Desethylchloroquine was also slowly cleared from plasma and mean concentration at the end of 7 days was 49% of the mean concentration at the end of 3 days.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661356      PMCID: PMC1428335          DOI: 10.1111/j.1365-2125.1983.tb02244.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Improved fluorimetric assay of chloroquine in biological samples.

Authors:  S A Adelusi; L A Salako
Journal:  J Pharm Pharmacol       Date:  1980-10       Impact factor: 3.765

2.  Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography.

Authors:  G Alván; L Ekman; B Lindström
Journal:  J Chromatogr       Date:  1982-04-16

3.  Kinetics of the distribution and elimination of chloroquine in the rat.

Authors:  S A Adelusi; L A Salako
Journal:  Gen Pharmacol       Date:  1982

4.  Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics.

Authors:  M Frisk-Holmberg; Y Bergkvist; B Domeij-Nyberg; L Hellström; F Jansson
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

5.  Chloroquine resistance produced in vitro in an African strain of human malaria.

Authors:  P Nguyen-Dinh; W Trager
Journal:  Science       Date:  1978-06-23       Impact factor: 47.728

6.  Variations in drug free fraction during alcohol withdrawal.

Authors:  P Sandor; C A Naranjo; V Khouw; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

7.  Chloroquine sensitivity of Plasmodium falciparum in Ibadan, Nigeria.

Authors:  A F Aderounmu; L A Salako; S A Adelusi
Journal:  Trans R Soc Trop Med Hyg       Date:  1980       Impact factor: 2.184

8.  Kinetics of the uptake and elimination of chloroquine in children with malaria.

Authors:  S A Adelusi; A H Dawodu; L A Salako
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

9.  Chloroquine sensitivity of Plasmodium falciparum in Ibadan, Nigeria: II. Correlation of in vitro with in vivo sensitivity.

Authors:  A F Aderounmu; L A Salako; O Walker
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

10.  The in vivo sensitivity of Plasmodium falciparum to chloroquine and to sulphadoxine-pyrimethamine combination in Ibadan, Nigeria.

Authors:  A Olatunde; L A Salako; O Walker
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

View more
  36 in total

1.  Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria.

Authors:  E Pussard; J P Lepers; F Clavier; L Raharimalala; J Le Bras; M Frisk-Holmberg; Y Bergqvist; F Verdier
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

3.  Drug use before hospital admission in Zimbabwe.

Authors:  H G Taylor; C M Stein; G Jongeling
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  A specific ELISA method for determining chloroquine in urine or dried blood spots.

Authors:  V Rowell; F J Rowell; A Baker; D Laurie; A M Sidki
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

Review 5.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

Review 6.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

7.  High-dose primaquine regimens against relapse of Plasmodium vivax malaria.

Authors:  Srivicha Krudsood; Noppadon Tangpukdee; Polrat Wilairatana; Nantaporn Phophak; J Kevin Baird; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2008-05       Impact factor: 2.345

8.  Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen.

Authors:  Celestino Obua; Urban Hellgren; Muhammed Ntale; Lars L Gustafsson; Jasper W Ogwal-Okeng; Toufigh Gordi; Markus Jerling
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

9.  Cardiovascular toxicity and distribution kinetics of intravenous chloroquine.

Authors:  S Looareesuwan; N J White; P Chanthavanich; G Edwards; D D Nicholl; C Bunch; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.